Agoracom Blog Home

Posts Tagged ‘tsx’

« Older Entries
Newer Entries »

4 Reasons Why The EdTech Industry Is Set To Take Off – SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 4:56 PM on Tuesday, February 25th, 2020
SPONSOR:  BetterU Education Corp. aims to provide access to quality education from around the world. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated ecosystem. Click here for more information.

4 Reasons Why The EdTech Industry Is Set To Take Off

  • Education Sector is Ripe for Disruption
  • Increasing User Base of Mobile Phones and Internet
  • The Young Are Leading the Way
  • Personalization of Education  

By: Neetin Agrawal Founder, Dronstudy

With the influx of smart devices, Internet and advanced software, the scope of education is expanding to every nook and corner of India. The impact of edtech on not just the education sector but broadly on the society is applaud-worthy, which is why the edtech sector is also highly popular among aspiring start-ups.

Online learning and courses are growing at a rapid pace as professionals realize the lack of skill-based courses and poor infrastructure in the Indian education system is now affecting their careers. 

In the last few years, an increasing number of entrepreneurs have also realized the potential of edtech. The uptrend will continue, thanks to the Digital India campaign, the cultural importance of education in Indian society, and low mobile data prices.

Private equity and venture capitalfirms are also keenly investing in this sector and not just in K–12 (kindergarten to 12th grade) but also in online courses. Supplemental courses, test preparation, online certification and gamification have vast potential that is yet to be explored. 

Education Sector is Ripe for Disruption

The Indian education system has been following the same traditional approach for decades. Even though the Indian culture has always laid high emphasis on education, yet it has seen a minimal transformation. To reform the country into a digitally empowered nation, the Indian government has also launched the initiative Digital India. 

The education sector is ripe for disruption—ranging from government initiatives to steps taken by educational institutions. The country is seeing a massive wave of revolution in the edtech sector. Schools and universities are embracing digital educational tools, and even offices are encouraging their employees to take up online courses to be more efficient and productive. 

Increasing User Base of Mobile Phones and Internet

The penetration of smartphones and cheap data rates has been a game-changer for the edtechs. Today, there are over 350 million mobile phone users in India, which is expected to double by 2022. With these numbers, there is no doubt that mobile phones and digital devices are the classrooms of the future. 

Online courses, virtual classrooms, digital teaching tools in classes, and through the increasing use of cutting-edge technologies such as virtual reality, artificial intelligence and augmented reality, the delivery and methodology of learning is changing. Not just the learners and educators, but entrepreneurs are becoming increasingly aware of the potential of technology in education.

The Young Are Leading the Way 

The workplaces have changed drastically, and the education system must change along. The edtech sector is helping fill the gaps between the education system and the professional world—it is aiding individuals to develop practical skills in addition to the theory taught in classrooms. 

Edtech entrepreneurs, or edupreneurs, are mostly young minds who are passionate about technology and aspirational. They are revolutionizing the education sector by launching unique initiatives and balancing technology with learning, helping it reach students, teachers and parents across metros, and tier II and III cities.

Personalization of Education 

With technology, the educators (teachers, professors, and educational institutions) will be able to strategize and customize the syllabi as per each student. The various educational programmes today are addressing the distinct interests, learning requirements and aspirations of a learner structure. 

Online courses are offering the masses a flexible and affordable way to acquire new skills. The advancements in education are helping people access education easily, rise above traditional bookish knowledge, and gain a better understanding of a subject through videos, online study material and educational apps with a variety of learning tools. 

Education in India is yet to go a long way, but the edtech sector is overcoming the hurdles one at a time.

Source: https://www.entrepreneur.com/article/346750

Tags: , , , , ,
Posted in All Recent Posts, betterU Education Corp | Comments Off on 4 Reasons Why The EdTech Industry Is Set To Take Off – SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca

INTERVIEW: Hollister $HOLL.ca Signs $20M LOI To Acquire Venom With $16.4M Revenue & $2.48M EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 4:00 PM on Tuesday, February 25th, 2020

At a time when Cannabis stocks are struggling and in a massive state of flux, due to an inability to actually deliver real businesses, Hollister Biosciences (HOLL:CSE) has been quietly building a real business, products, revenue and customers in 220 of California’s 600 dispensaries …. and growing, including California’s #1 hash infused pre-roll “Hashbone”.  

In addition to that, Hollister has also signed LOI’s, JV’s and licensing deals with major partners with massive nationwide and even global audiences launching in the next couple of months.  We’ll save details of those for another day but suffice it to say one of those partners is the world renowned Tommy Chong (of Cheech & Chong) who stated:

“I only partner with the best-in-class companies and I am really pleased to have the Hollister Cannabis Co. bring their amazing Tommy Chong’s Cannabis™ Full Spectrum Elixir to the market for me”.   

If that was all Hollister had going, they’d be in great shape with a super bright future and better than most Cannabis companies (small and large) who can’t even get product out the door.  

BUT THERE’S MORE – THE $20,000,000 ACQUISITION THAT COMES WITH $CDN 16.4M REVENUE & $CDN 2.48M EBITDA  

Earlier today, Hollister announced an LOI to acquire Venom Extracts, one of Arizona’s largest producers of Award-Winning Medical Cannabis Distillate. Just how good is Venom? In 2019, Venom generated $CDN 16.4M in revenue and $CDN 2.48M EBITDA in 2019 (subject to due diligence confirmation) … and all of that was just from the state of Arizona! Venom CEO Mason Cave and his team have aggressive plans to expand its brand and success into other states, including California as it benefits from Hollister’s distribution into 220 dispensaries.  

If you think “growth talk is cheap” (which is often the case), consider the fact that 30% of Venom’s $20,000,000 sale price kicks in if/when revenues hit $CDN 30,000 and $CDN 40,000 …. by December 31, 2021.  In my experience, companies joining forces don’t include such terms if there isn’t a reasonable expectation for hitting those numbers.  It doesn’t guarantee it but you can bet they have good reason to believe Venom sales will get to one or both of those numbers in just 21 months from now.  

If you’re looking for Cannabis companies that are going to survive and thrive over this next decade, then grab your favourite beverage and watch this interview with Hollinger President, Alex Somjen.  

We loved what we heard and look forward to your feedback in Hollister’s CEO Verified Forum below!

https://agoracom.com/ir/HollisterBiosciences

Tags: , , , , , , ,
Posted in All Recent Posts, Featured | Comments Off on INTERVIEW: Hollister $HOLL.ca Signs $20M LOI To Acquire Venom With $16.4M Revenue & $2.48M EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Empower Clinics $CBDT.ca to Create #Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 6:10 AM on Tuesday, February 25th, 2020
  • Company intends to utilize its database of 165,000 patients to further psilocybin research, develop new products and partner with global leaders in the field
  • “Empower is uniquely positioned to immediately impact research, develop new products and bring advancements to plant-based therapies, under a framework of rapidly increasing awareness and a movement toward decriminalization of psychedelic treatment options.” said Steven McAuley, Chairman & CEO of Empower

VANCOUVER, BC / February 25, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented life sciences company is pleased to announce it intends to leverage its existing clinic network, the developing franchise brand, its 165,000 patients and product development capability, to create psilocybin and psychedelics subsidiaries.

The Company has been conducting market research on advancements in psilocybin and psychedelics in North America and globally, along with building the business case internally on how to create greater shareholder value, utilizing Company assets that include clinics, patients, physicians and technology.

“There is an undeniable mental health crisis in our country and around the world, that has an ever-increasing, devastating affect on our society.” said Steven McAuley, Chairman & CEO of Empower. “Empower is uniquely positioned to immediately impact research, develop new products and bring advancements to plant-based therapies, under a framework of rapidly increasing awareness and a movement toward decriminalization of psychedelic treatment options.”

Studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin has shown efficacy, tolerability, and safety in the treatment of a variety of mental health conditions, including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress.

“Over the past seven years, we have assisted over one hundred thousand patients obtain access to alternative health care and medicinal cannabis. The provision of legal access to psilocybin therapies are perfectly in-line with our philosophy of providing a Scientific Approach to Alternative Medicine™“, said Dustin Klein, SVP Business Development and Director, Empower Clinics Inc. “Clinical trials have shown that psilocybin therapies provide tremendous help with conditions we see everyday in our clinics. It is our responsibility, to make sure we are providing the most up-to-date alternative therapies to our patients and our community.”

The mental health crisis could cost the world $16 trillion by 2030 and according to Future Market Insights; the global behavioral health (non-pharmacological) market is expected to be valued at US$156 billion by 2028.

The United States Food and Drug Administration has determined that preliminary clinical evidence indicates psilocybin may demonstrate substantial improvement over other available therapies for treatment-resistant depression; and granted a Breakthrough Therapy designation for a treatment that uses psilocybin as a therapy for such depression.

The Company also announces it has issued to Haywood Securities Inc., 4,000,000 common shares of the Company (the “Work Fee Shares”) under the financial advisory agreement dated September 25, 2019 (the “Agreement”) based on Haywood Securities Inc. completing the final written SWOT analysis. The shares issued are priced at fair market value of the common shares of the Corporation as at the date of issuance of the Work Fee Shares.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca to Create #Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Hollister Biosciences $HOLL.ca Signs Letter of Intent to Acquire Venom Extracts With $16.4 Million In Revenue And $2.48 Million EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 6:02 AM on Tuesday, February 25th, 2020
  • Company signed a Letter of Intent to acquire Venom Extracts
  • One of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.
  • Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges.

Hollister Biosciences Inc., the creator of California’s #1 hash-infused pre-roll HashBone, enters into Letter of Intent to acquire Venom Extracts, one of Arizona’s largest producers of award-winning medical cannabis distillate and related products

VANCOUVER, Feb. 25, 2020 – Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a vertically integrated cannabis branding company with products in 220 dispensaries throughout California, is pleased to announce that the Company signed a Letter of Intent (“LOI“) on February 20th, 2020 to acquire Venom Extracts ( “Venom“), one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.

HIGHLY ACCRETIVE $20,000,000 ACQUISITION

For the year ended December 31, 2019, Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges. Hollister cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by Venom management. Though Hollister believes the figures to be highly reliable, their audit will be part of the due diligence before closing.   

The all stock purchase price is anticipated to be CDN$ 20,000,000, with 70% to be paid upfront and 30% to be paid upon milestone achievements. The acquisition is expected to close by March 31, 2020 subject to normal course due diligence. 

 “Venom has established itself as a leading extraction operation with a prominent brand in the Arizona marketplace”, said Carl Saling, Founder and CEO of Hollister Biosciences Inc.  “We feel this acquisition will present a great deal of opportunity for synergy between Hollister and Venom, providing avenues for both companies into the Arizona, California and additional marketplaces for cannabis products.  Venom Extracts has a highly skilled and experienced management team with a track record for operational excellence.  This transaction is highly accretive and represents a fundamental part of the future growth of both companies.”

LOI TERMS

The terms of the LOI, which will be formalized by a definitive agreement on closing, are as follows:

  • The Company will acquire Venom Extracts for CDN$20,000,000 with such payment to be issued in Hollister common stock (the “Payment Shares“)
  • The stock price will be determined based on the greater of:
    • The 14-day VWAP (Volume Weighted Average Price) capped at $0.25 subsequent to announcing the transaction and $0.20
  • Once the share price is established, 70% of the Payment Shares will be issued upon closing of the transaction, subject to hold periods.
  • The remaining 30% of the Payment Shares will be issued when and if the following milestones have been met on or prior to December 31st, 2021:
    • 20% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 30,000,000 (calculated in accordance with IFRS from January 1, 2020).
    • 10% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 40,000,000(calculated in accordance with IFRS from January 1, 2020).

“We are very pleased to be entering into this transaction with Hollister”, shared Mason Cave, CEO of Venom Extracts.  “The opportunities for resource and capability sharing between the two companies are plentiful.  This also represents a more expeditious avenue for us into the large and rapidly growing California marketplace.  Hollister has an excellent management team in place and has established itself as a sought-after brand house of popular cannabis and hemp products in California.  We feel that our contribution on the extraction side will help diversify Hollister’s product offering and continue to build out the brand equity of both companies across multiple state and eventually global marketplaces”

In association with the arm’s length transaction, Hollister will not be assuming any long-term debt, a new control position will be created and there is no change in Management, or the Board of Directors of Hollister being contemplated at this time.

Finder’s fees will be payable in accordance with the policies of the Canadian Securities Exchange.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a vertically integrated cannabis company with multiple, high-quality products now carried in 220 of Indus Holdings (CSE: INDS), Hollister’s exclusive distribution partner’s 600 dispensaries. This level of penetration is expected to grow as the Company accelerates its seed to shelf, high margin business and product development model.

Capitalizing on this success, Hollister’s vision is to become the sought-after premium brand portfolio of innovative, high quality cannabis across multiple states and hemp products nationwide.

Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California, the birthplace of the “American Biker” from which we embrace the outlaw roots of Hollister to drive our Company fearlessly down the road of success.

Products from Hollister Cannabis Co. include HashBone, the brand’s premier artisanal hash-infused pre-roll ranked as California’s #1 hash infused pre-roll, along with solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures.

Website:  www.hollistercannabisco.com 

About Venom Extracts

Venom Extracts is one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.  With an experienced management team and unparalleled reputation for quality, Venom Extracts prides itself as a differentiated extraction company by producing legal Marijuana products at a price point that allows retailers to generate higher profits.  Focused on proprietary efficiencies, the Company is able to produce more product per square foot than its competition, maintaining lower costs and risks than a typical extraction company. The company’s expansion strategy is centered on entering new markets/states that are approved for medical cannabis use and/or approved or have a reasonable expectation to be approved for recreational use in the near future. 

Website:  www.venomextracts.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile onwww.sedar.com

million-ebitda-301010229.html

SOURCE Hollister Biosciences Inc.

Tags: , , , , , ,
Posted in Featured, Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca Signs Letter of Intent to Acquire Venom Extracts With $16.4 Million In Revenue And $2.48 Million EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

INTERVIEW: As Cannabis Companies Struggle, $MOTA.ca Delivers $29M Revenue, $3.6M EBITDA – And That’s Just The Start $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 4:03 PM on Monday, February 24th, 2020

In 1948, Winston Churchill said, “Those who fail to learn from history are condemned to repeat it”.  Unfortunately, many Cannabis companies aren’t historians and are repeating the dot-com to dot-bomb cycle of raising tons of money but no clue how to build a real business with it.

You know what else we learned from that cycle?  Web 2.0 was the birth of companies with real business plans, products, customers and revenues.  They went on to dominate the next 20 years.

Enter MOTA Ventures (MOTA:CSE), who has become a leader in online CBD sales into the North American market, thanks to an e-commerce “engine” built by CEO Ryan Hoggan and his team over the past few years at Unified Funding.  That engine is so powerful that is has racked up over $200 MILLION in sales from over 1 million paying customers over a number of products, including CBD sales of $25 MILLION by “First Class CBD”, which was acquired by MOTA for $32 MILLION.

As the new CEO of MOTA, Ryan is bringing that ecommerce engine into the Company to further drive CBD sales into the US market, as well as, Europe.  As an online company ourselves, we can pretty easily spot companies that are just trying to piggy back “e-commerce”.  Ryan is the real deal.  As you will hear in this interview, he has already achieved monster e-commerce success with the likes of Boeing, Daimler and the Lakers basketball team on over 100 health and wellness products.

The best part for MOTA shareholders?  Ryan is highly motivated to continue with his successful ways because Unified Funding can earn an additional $15 MILLION if First Class CBD achieves sales of $62 MILLION.  In my experience, companies don’t put bonuses into contracts unless they both believe there is a reasonable belief they can be achieved. Will he hit $62M?  Or fall short at the other 2 milestones of $52M and $42M?

Watch this interview and you be the judge.  Either way, MOTA shareholders should get their popcorn ready because Ryan has already proven he’s leading MOTA into the Cannabis 2.0 phase.  Success is already here, now its just a question of how high MOTA will fly.

Watch this interview and share it with every investor you know!

Tags: , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, Mota Ventures Corp. | Comments Off on INTERVIEW: As Cannabis Companies Struggle, $MOTA.ca Delivers $29M Revenue, $3.6M EBITDA – And That’s Just The Start $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Mota Ventures $MOTA.ca Announces Transition After Definitive Close of First Class #CBD Acquisition; Ryan Hoggan is New CEO $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 7:34 AM on Saturday, February 22nd, 2020
  • Announced a transition after the definitive close of First Class CBD acquisition
  • Appointed Ryan Dean Hoggan to Chief Executive Officer
  • Acquisition of First Class CBD coupled with the upcoming U.S. roll out of the Company’s European CBD brand, Sativida, made the appointment of Mr. Hoggan to Chief Executive Officer a natural fit
  • Mr. Hoggan brings more than 18 years of leadership, global business development and entrepreneurship experience in the health equipment, medical devices and natural health products sectors

VANCOUVER, BC / February 22, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the “Company” or “Mota“) is pleased to announce a transition after the definitive close of First Class CBD acquisition, the Company’s Board of Directors has appointed Ryan Dean Hoggan to Chief Executive Officer. The acquisition of First Class CBD coupled with the upcoming U.S. roll out of the Company’s European CBD brand, Sativida, made the appointment of Mr. Hoggan to Chief Executive Officer a natural fit. Ryan brings a wealth of expertise to this role, being one of the founders of Unified Funding LLC and First Class CBD. Ryan is an experienced strategist, with a strong understanding of building high value consumer brands with significant annual revenue. Ryan’s extensive background in the online e-commerce space will continue to drive the Company’s rapid growth in the US and spearhead its expansion into the European market. The Company intends to continue its roll up strategy of acquiring profitable, well-known CBD brands globally.

Mr. Hoggan brings more than 18 years of leadership, global business development and entrepreneurship experience in the health equipment, medical devices and natural health products sectors. Early in his career, Ryan took on a leadership role in his family business, HOGGAN Health Industries, where he led operations, business development and marketing efforts. After identifying an untapped niche in the market, he founded Hoggan Medical where he went on to launch over 100 health, fitness and medical device products and negotiated contracts with big and small customers including the Mayo Clinic, Boeing, Daimler AG and the Los Angeles Lakers (NBA).

In 2014, Ryan discovered the power of CBD and essential oils – both personally and professionally – after a personal health scare prompted him to research and subsequently try holistic products to improve his health. The experience ultimately led him to become a Partner and President of Offer Space, LLC and Real Oil, LLC, two rapidly growing E-commerce and technology companies focused on serving U.S. based and international consumers in the CBD and natural health products market. In June 2019, Mr. Hoggan led a strategic divestiture of the businesses to Unified Funding, LLC to help continue an impressive growth trend. Through the operations of Unified Funding, LLC, the business has generated a database of over 4.5 million customer records and facilitated over $200 million in consumer transactions from more than one million paying customers in sectors such as beauty, nutrition and CBD products.

Mr. Hoggan holds a Bachelor of Business Administration (BBA) from Westminster College, an MBA from The University of Arizona and a Master of Global Management (MGM) from the Thunderbird School of Global Management at Arizona State University.

In connection with Ryan’s appointment to CEO, Joel Shacker will transition to the role of President of the Company and will remain a member of the board of directors.

“I am very excited to take on the CEO role at Mota and focus the operations on becoming a global E-commerce CBD company. I am also excited about the partnership between Unified and Sativida. Unified’s extensive experience in the U.S. and strong logistics and supply chain will provide significant support for the launch of the Sativida line in the U.S. I believe through the direct-to-consumer online platforms we will become a leader in the CBD space. We plan to aggressively expand First Class’s existing operations in the U.S. as well as launch a European expansion, which we anticipate will yield similar results to our U.S. operations last year,” stated Ryan Hoggan, CEO of the Company.

“We are extremely happy to have someone with Ryan’s extensive experience stepping into this role. I am confident in his ability to execute on expanding operations and generating further revenue. I look forward to continuing to build the Company in my new role as President and to working with Ryan during his transition to CEO of Mota.” stated Joel Shacker.

About Mota Ventures Corp.

Mota is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Joel Shacker

President

For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the Company’s rapid growth in the US and expansion into the European market, its plans to become a vertically integrated global CBD brand, its plans to cultivate and extract cannabis to produce CBD and high-quality value added CBD products in Latin America for distribution domestically and internationally and its plans to acquire revenue-producing CBD brands and operations in Europe and North America. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

SOURCE: Mota Ventures Corp.

Tags: , , , , , , ,
Posted in Featured, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Announces Transition After Definitive Close of First Class #CBD Acquisition; Ryan Hoggan is New CEO $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

#Mhealth Device Market is Booming Worldwide – SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 11:30 AM on Friday, February 21st, 2020

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

M-Health Device Market is Booming Worldwide

  • Mhealth field has emerged as a sub-segment of eHealth, the use of information and communication technology (ICT), such as computers, mobile phones, communications satellite, patient monitors, etc., for health services and information.
  • According to an analyst firm, around 2.8 million patients worldwide were using a home monitoring service based on equipment with integrated connectivity

By Orian Research on February 21, 2020

According to a Latest market research report titled, ‘M-Health Device Market’, added on Orian Research. The report has been processed on the basis of a comprehensive analysis with inputs from industry experts. The report presents the market scenario and its potential growth prospects during the forecast period. The report also presents the evaluation of the competitive landscape of the market. The leading strategies, collaborations, innovations, and market revenue of the major players has been elaborated in this report. The approvals and insights on the top companies prevalent in the market will enable the reader to get accustomed with the market opportunities that they can tackle with informed and favorable business strategies

mHealth is an abbreviation for mobile health, a term used for the practice of medicine and public health supported by mobile devices. The term is most commonly used in reference to using mobile communication devices, such as mobile phones, tablet computers and PDAs, and wearable devices such as smart watches, for health services, information, and data collection. The mHealth field has emerged as a sub-segment of eHealth, the use of information and communication technology (ICT), such as computers, mobile phones, communications satellite, patient monitors, etc., for health services and information.

According to an analyst firm, around 2.8 million patients worldwide were using a home monitoring service based on equipment with integrated connectivity at the end of 2013. The figure does not include patients that use monitoring devices connected to a PC or mobile phone. It only includes systems that rely on monitors with integrated connectivity or systems that use monitoring hubs with integrated cellular or fixed-line modems.

Global M-Health Device Industry 2020 Market Research Report is spread across 95 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. The report focuses on global major leading M-Health Device Industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information.

The M-Health Device market report is a collection of the first-hand data, subjective, and quantitative assessment by industry experts and professionals, contributions from industry specialists and industry participants over the value chain. The report consists of a detailed analysis of the industry growth trends, micro- and macroeconomic components, and governing factors, along with the market attractiveness, within the market segments. The report likewise maps the subjective impact of the different market factors on the market segments, sub-segments, and geographies.

Major Players in M-Health Device Market are:
• Allscripts
• Apple
• Athenahealth
• Cerner
• Ge Healthcare
• Philips
• Medtronics

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of M-Health Device market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research.

All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

Source: https://www.instanttechnews.com/technology-news/2020/02/21/m-health-device-market-is-booming-worldwide-technology-trends-players-allscripts-apple-athenahealth-cerner-ge-healthcare-philips-medtronics/

Tags: , , , , ,
Posted in CardioComm Solutions | Comments Off on #Mhealth Device Market is Booming Worldwide – SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Iconic $ICM.ca Provides Update on Drilling Program and Phase 2 Metallurgical Testing For Bonnie Claire #Lithium Project, Nevada $LI.ca $MGG.ca $PAC.ca $CYP.ca $NEV.ca

Posted by AGORACOM-JC at 10:15 AM on Thursday, February 20th, 2020
  • Announced that it is planning a spring drilling campaign as soon as the weather is conducive for entry into the Bonnie Claire Lithium Deposit in Nevada
  • Iconic has received an update from St-Georges Eco-Mining Corp. regarding Phase 2 metallurgical testing of the lithium-rich sediment from Iconic’s Bonnie Claire lithium deposit in Nevada

Vancouver, British Columbia–(February 20, 2020) – Iconic Minerals Ltd. (TSXV: ICM) (OTC Pink: BVTEF) (FSE: YQGB) (“Company” or “Iconic”) is pleased to announce that it is planning a spring drilling campaign as soon as the weather is conducive for entry into the Bonnie Claire Lithium Deposit in Nevada.

Iconic has received an update from St-Georges Eco-Mining Corp. (“St-George”) (CSE: SX) regarding Phase 2 metallurgical testing of the lithium-rich sediment from Iconic’s Bonnie Claire lithium deposit in Nevada. Iconic is encouraged by this update and is sending additional drill cuttings to meet St-Georges’ requests and allow further progress toward completing the Phase 2 report.

St-Georges is proceeding with the next stages of tests within Phase 2, where its current focus is the optimization of chemicals consumption and purification steps to meet the requirements for lithium hydroxide. Iconic looks forward to receiving further metallurgical results from St Georges.

The Bonnie Claire Lithium Property Characteristics:

The Property is located within Sarcobatus Valley that is approximately 30 km (19 miles) long and 20 km (12 miles) wide. Quartz-rich volcanic tuffs, that contain anomalous amounts of lithium, occur within and adjacent to the valley. Geochemical analysis of the local salt flats has yielded lithium values up to 340 ppm. The gravity low within the valley is 20 km (12 miles) long, and the current estimates of depth to basement rocks range from 600 to 1,200 meters (2,000 to 4,000 feet). The current claim block covers an area of 35 km2 (13.5 mi2) with potential to be underlain by lithium-rich sediments.

On behalf of the Board of Directors

SIGNED: “Richard Kern“

Richard Kern, President and CEO
Contact: Keturah Nathe, VP Corporate Development (604) 336-8614

For further information on ICM, please visit our website at www.iconicminerals.com
The Company’s public documents may be accessed at www.sedar.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52593

Tags: , , , , , , ,
Posted in Iconic Minerals | Comments Off on Iconic $ICM.ca Provides Update on Drilling Program and Phase 2 Metallurgical Testing For Bonnie Claire #Lithium Project, Nevada $LI.ca $MGG.ca $PAC.ca $CYP.ca $NEV.ca

BEYOND THE DECK: $HPQ.ca Silicon Shares Its PowerPoint Presentation With Investors $FSLR $SPWR $CSIQ $PYR.ca $XMG.ca

Posted by AGORACOM-JC at 9:21 AM on Thursday, February 20th, 2020

Tags: , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, HPQ-Silicon Resources Inc. | Comments Off on BEYOND THE DECK: $HPQ.ca Silicon Shares Its PowerPoint Presentation With Investors $FSLR $SPWR $CSIQ $PYR.ca $XMG.ca

Empower Clinics $CBDT.ca – #Cannabis Extraction Stocks Best Profit Play for #Marijuana Investors $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 5:44 PM on Wednesday, February 19th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025

Cannabis Extraction Stocks Best Profit Play for Marijuana Investors

Cannabis Extraction Stocks on Pace for Massive Growth

  • Cannabis extraction companies are at the center of the hottest trend to hit the legal cannabis industry in years: marijuana derivatives
  • Those include cannabis-infused products like edibles, vapes, concentrates, beverages, tinctures, and topicals.

By John Whitefoot, BA

In the lead-up to the October 2018 legalization of recreational cannabis in Canada, all eyes were on marijuana growers. It made sense. They were the companies that were going to supply the industry with dried flower. And demand for weed was expected to go through the roof.

While 2019 was a tough year for some pot stocks, 2020 is shaping up to be much better. Not all pot stocks are created equal though. One area that looks like it’s poised to outstrip the broader weed stock market is cannabis extraction stocks.

In 2019, global pot sales soared 48% year-over-year to $15.0 billion. In 2020, marijuana sales are expected to climb 38%. By 2024, global weed sales are projected to top $43.0 billion.  (Source: “Global Cannabis Sales Grow 48% to $15 Billion in 2019,” BDS Analytics, January 16, 2020.)

A compound annual growth rate of 23% is pretty hard to dismiss.

Legal marijuana is a young industry that is providing investors with a lot of choices. In addition to the marijuana producers, there are companies that serve or support those producers—with elements such as hydroponics, processing, extraction, financing, set-up, e-commerce, and operating dispensaries.

So far they have mostly been serving the relatively small Canadian market (Canada has a population less than that of California)—one that, as of September 2019, had yet to generate $1.0 billion in annual legal pot sales. (Source: “The Retail Cannabis Market in Canada: A Portrait of the First Year,” Statistics Canada, Statistics Canada, December 11, 2019.)

That number will likely jump considerably once the Canadian marijuana market matures. Investors who do not want to wait for that to happen, however, might want to consider cannabis extraction stocks.

Why? Cannabis extraction companies are at the center of the hottest trend to hit the legal cannabis industry in years: marijuana derivatives. Those include cannabis-infused products like edibles, vapes, concentrates, beverages, tinctures, and topicals.

Cannabis-Infused Products Are Crucial for the Pot Industry

Cannabis-infused products are opening up a whole new revenue stream for the legal marijuana industry. That’s because these items are being introduced to consumers who may have been reluctant to try traditional cannabis products. Some people like the buzz or the medicinal properties but don’t want to inhale smoke.

A few years ago, in the U.S., roughly 75% of the marijuana market was taken up by cannabis flower. Today that number is around 40%. A similar trend has been happening in Canada. (Source: “Why Business Is Booming for Cannabis Extraction Companies Despite the Supply Shortage,” Financial Post, April 19, 2019.)

That is a godsend for marijuana companies looking to juice their top and bottom lines. That’s because cannabis-infused products have higher margins than traditional dried cannabis does.

Providing products that have high demand and a high profit margin is a no-brainer.

Cannabis Extract Industry Will Be Huge

In January 2020, cannabis-infused products legally hit store shelves in Canada for the first time. That came just a year after the Canadian government approved the sale of recreational marijuana in the form of dried flower, oils, and sprays.

The cannabis extraction industry will be massive, because the sales projections for pot-infused products are huge.

According to one study, the total legal marijuana market in Canada will reach $11.0 billion by 2025. Of that, 54% is expected to come from sales of edibles and other cannabis-extract products. (Source: “One-in-five Canadians will consume cannabis in 2025: Ernst & Young,” Yahoo! Finance Canada, March 26, 2019.)

And that’s just for Canada; the global market for cannabis derivatives is expected to nearly double over the next five or six years to $194.0 billion. (Source: “Canada’s consumer market for edibles estimated to reach at least $1.6 billion annually: Deloitte,” The GrowthOp, June 3, 2019.)

Now, many cannabis companies do not have in-house extraction facilities. To make marijuana-infused products, they need to outsource the work. That’s where cannabis extraction companies come into play.

Instead of growing marijuana, they take hemp and cannabis biomass and process it for the resins, concentrates, distillates, and targeted cannabinoids.

Admittedly, some of the bigger licensed marijuana growers in Canada already have—or are constructing—their own extraction facilities, but it won’t be enough to meet the future demand for cannabis oils.

In fact, some cannabis growers have signed multi-year, renewable extraction agreements with the bigger cannabis extraction companies in Canada.

Analyst Take

Cannabis extraction stocks could be a huge profit opportunity for marijuana investors. Marijuana-infused products became legal in Canada at the start of 2020, and the industry is expected to experience double-digit growth over the coming years.

Thanks to higher margins, more and more companies are looking to produce cannabis-infused products. If marijuana-derivative products sell well, cannabis extract stocks should rise in value.

Source: https://www.profitconfidential.com/marijuana/cannabis-extraction-stocks-best-profit-play-marijuana-investors/

Tags: , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca – #Cannabis Extraction Stocks Best Profit Play for #Marijuana Investors $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

« Older Entries
Newer Entries »